mRNA
Moderna Thursday said it paused plans to build an mRNA manufacturing facility in Kenya to buy time to assess vaccine demand after being hit with $1 billion in losses and write-downs due to canceled orders.
As JPM week draws close, Lilly CEO David Ricks talks about what he thinks is in store for the biopharma industry.
There seems to be decidedly positive sentiment regarding biopharma in 2024—perhaps a harbinger of things to come this year coming off a topsy-turvy 2023.
A lot of attention at JPM was focused on the cancer space. Executives from Olema Oncology and Cyclacel spoke with BioSpace about their plans for 2024 and why biotech’s kickoff conference is important to them.
The BioSpace team is recording from San Francisco as they bring you the the latest highlights from Day 3 at JPM2024.
The BioSpace team is recording from San Francisco as they bring you the the latest highlights from Day 2 at JPM2024.
The BioSpace team is recording from San Francisco as they bring you the the latest highlights from JPM2024.
BioSpace continues to bring you the latest news and industry developments from the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco. Stay tuned!
Pfizer and BioNTech scored a win over Moderna on Tuesday as the European Patent Office decided that a key patent held by the Massachusetts biotech related to its COVID-19 vaccine is invalid.
Watch this webinar to gain insights from expert speakers, Dr. Iris Alroy and Dr. Kristopher Brannan, who have made significant advancements in the field of RBPs.
PRESS RELEASES